These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30699195)

  • 1. Correction: Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.
    Tokai N; Yoshida S; Kotani T; Yoshikawa A; Kimura Y; Fujiki Y; Matsumura Y; Takeuchi T; Makino S; Arawaka S
    PLoS One; 2019; 14(1):e0211750. PubMed ID: 30699195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.
    Tokai N; Yoshida S; Kotani T; Yoshikawa A; Kimura Y; Fujiki Y; Matsumura Y; Takeuchi T; Makino S; Arawaka S
    PLoS One; 2018; 13(8):e0202601. PubMed ID: 30138480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
    Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
    Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
    Arita Y; Taguchi H; Kobayashi M; Tono T; Ohsone Y; Okano Y
    Mod Rheumatol; 2018 Nov; 28(6):1041-1043. PubMed ID: 27180974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.
    Xie S; Li S; Tian J; Li F
    Front Pharmacol; 2020; 11():488. PubMed ID: 32372962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
    Wang X; Ma C; Li P; Zhao F; Bi L
    Clin Rheumatol; 2017 Jun; 36(6):1369-1377. PubMed ID: 28474138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.
    Crowson CS; Rollefstad S; Kitas GD; van Riel PL; Gabriel SE; Semb AG;
    PLoS One; 2017; 12(4):e0175605. PubMed ID: 28388688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients.
    Dargham SR; Zahirovic S; Hammoudeh M; Al Emadi S; Masri BK; Halabi H; Badsha H; Uthman I; Mahfoud ZR; Ashour H; El Haq WG; Bayoumy K; Kapiri M; Saxena R; Plenge RM; Kazkaz L; Arayssi T
    PLoS One; 2019; 14(3):e0214258. PubMed ID: 30883600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis.
    Xu Y; Zhu Q; Song J; Liu H; Miao Y; Yang F; Wang F; Cheng W; Xi Y; Niu X; He D; Chen G
    Mediators Inflamm; 2015; 2015():356040. PubMed ID: 26713003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.
    Sung YK; Yoshida K; Prince FHM; Frits ML; Cho SK; Choe JY; Lee HS; Lee J; Lee SS; Yoo DH; Helfgott SM; Shadick NA; Weinblatt ME; Solomon DH; Bae SC
    PLoS One; 2019; 14(8):e0221314. PubMed ID: 31412077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey.
    Jeong H; Baek SY; Kim SW; Eun YH; Kim IY; Kim H; Lee J; Koh EM; Cha HS
    PLoS One; 2017; 12(5):e0178309. PubMed ID: 28542532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis.
    Yang B; Huang Z; Feng W; Wei W; Zhang J; Liao Y; Li L; Liu X; Wu Z; Cai B; Bai Y; Wang L
    PLoS One; 2017; 12(3):e0173531. PubMed ID: 28253339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Chronic Hepatitis C Virus Infection Is Associated with the Development of Rheumatoid Arthritis: A Nationwide Population-Based Study in Taiwan.
    Su FH; Wu CS; Sung FC; Chang SN; Su CT; Shieh YH; Yeh CC
    PLoS One; 2016; 11(11):e0166508. PubMed ID: 27829054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis-A Meta-Analysis.
    Fisher A; Bassett K; Goel G; Stanely D; Brookhart MA; Freeman HJ; Wright JM; Dormuth CR
    PLoS One; 2017; 12(2):e0172646. PubMed ID: 28199406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis.
    Baghdadi LR
    PLoS One; 2020; 15(12):e0243960. PubMed ID: 33296441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    Wang KH; Wang YM; Chiu LH; Chen TC; Tsai YH; Zuo CS; Chen KC; Changou CA; Lai WT
    PLoS One; 2018; 13(8):e0202610. PubMed ID: 30107000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Wang XT; Li P; Xu TS; Ding R; Zhang X; Bi LQ
    Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):44-50. PubMed ID: 27894399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
    Luo Q; Sun Y; Liu W; Qian C; Jin B; Tao F; Gu Y; Wu X; Shen Y; Xu Q
    J Immunol; 2013 Nov; 191(10):4969-78. PubMed ID: 24123677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Interleukin-1 Receptor Antagonist Has a Novel Function in the Regulation of Matrix Metalloproteinase-13 Expression.
    Goto H; Ishihara Y; Kikuchi T; Izawa A; Ozeki N; Okabe E; Kamiya Y; Ozawa Y; Mizutani H; Yamamoto G; Mogi M; Nakata K; Maeda H; Noguchi T; Mitani A
    PLoS One; 2020; 15(4):e0231910. PubMed ID: 32275705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.